Cardiopatías Familiares e xenética cardiovascular
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublications in collaboration with researchers from David Geffen School of Medicine at UCLA (1)
2020
-
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet, Vol. 396, Núm. 10253, pp. 759-769